Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides

Area of Science:

• Oncology
• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Intratumoral heterogeneity (ITH) in malignant cells presents a significant challenge to effective cancer therapy.
• Existing treatments often struggle to overcome the diverse nature of cancer cells within a single tumor.
• Novel therapeutic strategies are needed to ensure treatment efficacy despite ITH.

Purpose of the Study:

• To review the therapeutic potential of oncolytic peptides in overcoming cancer treatment resistance due to ITH.
• To explore the molecular and immunological mechanisms by which oncolytic peptides induce anticancer effects.
• To discuss the combination of oncolytic peptides with modern immunotherapeutics for enhanced cancer treatment.

Main Methods:

• Literature review of preclinical and clinical evidence on oncolytic peptides.
• Analysis of molecular pathways targeted by oncolytic peptides.
• Examination of immunological responses elicited by oncolytic peptides.
• Discussion of potential combination strategies with immunotherapeutics.

Main Results:

• Oncolytic peptides induce immunogenic cell death, a process that can trigger robust anticancer immune responses.
• These responses are largely independent of the degree of intratumoral heterogeneity.
• Oncolytic peptides engage specific molecular and immunological pathways crucial for tumor targeting.

Conclusions:

• Oncolytic peptides represent a promising therapeutic modality for cancers characterized by significant ITH.
• Their ability to drive immunogenic cell death and stimulate immune responses offers a distinct advantage.
• Combining oncolytic peptides with other immunotherapies holds potential for improved tumor-targeting immunity and clinical efficacy.